GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: Jin Beixin® (China)
firsekibart is an approved drug
Compound class:
Antibody
Comment: Firsekibart (previously genakumab) is an IgG4λ monoclonal antibody that targets interleukin-1β (IL-1β). It was developed for anti-inflammatory potential. Based on peptide sequence matches for the heavy and light variable regions of firsekibart, this appears to be antibody 048Ab-4 (H2L6) in patent CN106928354A [2].
|
Classification ![]() |
|
| Compound class | Antibody |
| Approved drug? | Yes. China NMPA (2025) |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 13353 | firsekibart |
Synonyms ![]() |
| Jin Beixin® (China) |
Database Links ![]() |
|
| Specialist databases | |
| IMGT/mAb-DB | 1746 |
| Other databases | |
| GtoPdb PubChem SID | 523352191 |
| Search PubMed clinical trials | firsekibart |
| Search PubMed titles | firsekibart |
| Search PubMed titles/abstracts | firsekibart |